Eton Pharmaceuticals Announces Its ET-700 Zing Acetate Formulation Shows Lower Rate Of Drug Related Adverse Events In Pilot Trial Than GALZIN; No Serious Adverse Events Seen

Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced preliminary results from a randomized, double-blind, placebo-controlled pilot study evaluating ET-700, its investigational extended-release zinc acetate formulation being developed to treat Wilson disease.

ET-700 demonstrated a lower rate of drug related adverse events than GALZIN, with participants who received ET-700 reporting a single gastrointestinal-related adverse event. In comparison, 8 out of 12 participants receiving GALZIN reported 17 adverse events. Participants who received placebo reported 3 treatment related adverse events in 3 of the 12 participants. No serious adverse events were reported in the study. The estimated rate of treatment related gastrointestinal side effects was 0.30 per 100 participant-days for ET-700, compared with 5.35 for GALZIN and 0.89 for the placebo.